madman
Super Moderator
Abstract
INTRODUCTION AND OBJECTIVES:
Phosphodiesterase Type 5 (PDE5) inhibitor is effective in treating erectile dysfunction and is generally safe concerning cardiovascular (CV) risk profiles. We analyzed hazard ratio and 1-year outcome of major adverse cardiac events (MACE) to depending on different time the patient starts taking PDE5 inhibitor.METHODS:
Data from Global Collaborative Network with 155 healthcare organizations was retrieved. Fifty- to 70-year-old man diagnosed with erectile dysfunction after the first day of 2015 without secondary pulmonary hypertension one year ago or coronary artery disease 5 years ago was included. Those started taking PDE5 inhibitor (Sildenafil, Tadalafil, Vardenafil, and Avanafil) within one month since ED diagnosed was defined as Group A. Those who did not take PDE5 inhibitor was defined as Group B. Outcomes were assessed from day 1 to day 365 after the index event. Propensity score matching and Kaplan-Meier survival analysis was used for statistical analysis.RESULTS:
After propensity score matching, 336,795 patients were analyzed in each group with a median follow-up of 1 year. Group A patients were slightly older and had higher rates of chronic ischemic heart disease, chronic kidney disease, and COPD. They also showed lower creatinine, triglyceride, and HbA1c levels, but higher LDL and HDL cholesterol. Both mortality and cardiovascular outcomes favored Group A (Table 1).CONCLUSIONS:
Begin to take PDE5 inhibitor within 1 month once ED diagnosed has significant efficacy in lowering hazard ratio of 1-year all-cause mortality and MACE. It is worth noted that its protective effect still presents in those with systematic diseases.
